2022 Consensus Statement on Immune Checkpoint Inhibitor-Mediated Endocrinopathies

This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews the clinical presentation of ICI-related endocrinopathies; and discusses the diagnosis and management approaches to endocrinopathies related to ICI therapy.

Read Consensus Statement